Honey Bee (Api m 1) IgE Test · Blood

If you have had a serious reaction to a bee sting, knowing exactly which insect your immune system is reacting to is not a small detail. It determines whether you carry an epinephrine injector for life, whether you pursue venom immunotherapy, and which venom that therapy uses. Standard whole venom blood tests often light up positive for both bee and wasp at the same time, leaving the question unanswered.

This test measures IgE (immunoglobulin E, the antibody class your body makes during allergic reactions) directed specifically at Api m 1, the main allergen in honey bee venom. Because Api m 1 is highly specific to bees, a positive result is one of the cleanest signals that bee venom, not wasp, is the real culprit driving your allergy.

What Api m 1 Actually Is

Api m 1 (full name: bee venom phospholipase A2) is an enzyme produced inside the venom gland of the honey bee. When a bee stings you and you become sensitized, your immune system can make Api m 1 (phospholipase A2) IgE antibodies that recognize this single protein. Those antibodies circulate in your blood, and the test detects them. Api m 1 is considered the major allergen in honey bee venom because most bee-allergic people make IgE against it.

The test does not measure how severe your next sting reaction will be. It does not measure how much venom your body absorbed. It measures one specific fact: whether your immune system has built a targeted antibody response to the dominant protein in honey bee venom.

Why It Matters: Sorting Bee From Wasp

The single biggest practical use of this test is solving a problem that traditional venom testing creates. When a clinic runs IgE tests against whole bee venom and whole wasp venom, a large fraction of people test positive to both. Most of that double positivity is not real double allergy. It is caused by sugar structures (called cross reactive carbohydrate determinants, or CCDs) attached to many insect venom proteins that your antibodies can latch onto without it meaning anything clinically.

Api m 1 IgE cuts through this confusion. In one study of patients with double positivity to bee and wasp venom, measuring IgE to the species-specific markers Api m 1 (bee) and Ves v 5 (wasp) cleanly separated true double sensitization from cross-reactivity. Other research in 274 patients confirmed that recombinant Api m 1 and the wasp markers Ves v 1 and Ves v 5 can pull apart the real culprit when standard tests look ambiguous.

If you are weighing venom immunotherapy, which is a years-long treatment, knowing which venom to use is essential. Picking the wrong one wastes time and exposes you to unnecessary risk.

How Well the Test Performs

Api m 1 IgE is highly specific but only moderately sensitive. Across multiple cohorts, the test detects IgE in roughly 72 to 78 percent of people with confirmed honey bee venom allergy. With newer, more sensitive assay platforms (such as the Immulite system), sensitivity reaches about 88 percent with specificity between 94 and 98 percent. In control populations who are not bee-allergic, essentially no one tests positive.

Sources: Köhler et al. 2014, Šelb et al. 2016, Jovanovic et al. 2023.

What this means for you: a positive Api m 1 IgE strongly suggests genuine honey bee sensitization. A negative Api m 1 IgE does not rule out bee allergy on its own, because some bee-allergic people react mainly to other bee venom proteins like Api m 3, Api m 5, or Api m 10. About 5 out of 100 bee-allergic people would be missed if only Api m 1 were tested.

What the Test Cannot Predict

This is the part that surprises most people. Higher Api m 1 IgE levels do not reliably predict more severe sting reactions. In a study of 194 patients with insect venom allergies, neither skin tests nor serum IgE levels predicted the grade of anaphylaxis. Severe reactions occurred at low IgE titers, and milder reactions occurred at high titers. A 480-patient study found that other factors, like a short time between the sting and reaction, absence of skin symptoms, age, and baseline tryptase, were better indicators of severe systemic reactions.

The takeaway: a high number does not mean you are guaranteed to have anaphylaxis next time, and a low number does not mean you are safe. The test confirms sensitization and identifies the culprit insect. Predicting how bad your next reaction might be requires looking at the whole clinical picture, including your prior reaction history and baseline tryptase.

Bee Venom Allergy and Anaphylaxis Risk

The main condition linked to Api m 1 IgE is honey bee venom allergy with systemic sting reactions, which can include anaphylaxis. People with elevated baseline tryptase or underlying mastocytosis (a mast cell disease) sit in a higher overall risk group, and component-resolved testing including Api m 1 has been shown to accurately diagnose these high-risk patients.

In a cohort of 257 unreferred adults with high sting exposure, such as hunters and fishers, sensitization to bee venom components was common, and IgE patterns including Api m 1 helped define clusters of people at higher anaphylaxis risk. This was risk stratification within a high-exposure group, not a screening tool for the general public.

Role in Venom Immunotherapy Decisions

Venom immunotherapy (VIT) is the standard treatment for confirmed bee venom allergy with prior systemic reactions. Knowing your component pattern matters here too. One study of 64 bee venom allergy patients found that higher IgE against Api m 1 and Api m 5, combined with elevated tryptase, was associated with more allergic reactions and more therapeutic complications during VIT. Separately, predominant sensitization to Api m 10 (rather than Api m 1) has been linked to a higher risk of treatment failure.

If you are considering or already on VIT, Api m 1 IgE is part of the picture that helps your allergist anticipate how you may respond and whether the therapy needs adjustment.

When Results Can Be Misleading

A few situations can confuse the interpretation of Api m 1 IgE results.

• Cross-reactive carbohydrates on whole venom tests: if your clinic tested only whole bee venom (not Api m 1 specifically) and you came up positive, that result could be driven by sugar structures shared with pollen or other insects rather than true bee allergy. Api m 1 testing is what cuts through that noise.
• Other bee components carrying your allergy: a negative Api m 1 IgE does not rule out bee venom allergy. Roughly 5 out of 100 bee-allergic people are sensitized only to Api m 3 or Api m 10. If your history strongly suggests bee allergy but Api m 1 is negative, an extended component panel is the next step.
• Low positive predictive value in some populations: in a study of beekeepers, hunters, and other high-exposure groups, sensitization without prior systemic reactions was common. A positive Api m 1 in someone with no clinical history of a reaction does not automatically mean they will react to a future sting.
• Royal jelly exposure: in atopic dermatitis patients, royal jelly products have been associated with cross-reactive responses to honeybee venom, which can complicate test interpretation if exposure history is not collected.

Tracking Your Trend

A single Api m 1 IgE reading confirms whether you are sensitized at that moment in time. If you are not on treatment and your clinical situation is stable, the practical value of repeating it frequently is limited. The story changes if you start venom immunotherapy. Research on molecular diagnostics in 491 patients showed that VIT causes progressive but differential reduction in specific IgE over time, supporting the use of serial testing to monitor your immune response to treatment.

A reasonable pattern: get a baseline before any treatment decision, then retest periodically during VIT (typically annually, or as your allergist directs) to track how your antibody profile is changing. Outside of treatment, retest if your clinical situation shifts, such as after a new sting reaction or before stopping immunotherapy.

What to Do With an Unexpected Result

If your Api m 1 IgE is positive and you have a history of a systemic reaction to a bee sting, that combination supports a diagnosis of honey bee venom allergy. The next step is a conversation with an allergist about carrying epinephrine and whether venom immunotherapy makes sense for you. If you are positive for both bee (Api m 1) and wasp components (Ves v 1, Ves v 5) at clinically meaningful levels, you may have true double sensitization, which influences which venoms to use in immunotherapy.

If you have a strong clinical history of bee reaction but Api m 1 IgE is negative, do not assume you are not allergic. Ask about extending the panel to Api m 2, Api m 3, Api m 5, and Api m 10. A basophil activation test can also help in ambiguous cases. Baseline serum tryptase is worth checking alongside, especially if you have ever had a severe reaction, because elevated tryptase points toward an underlying mast cell condition that changes both risk and management.

If you are positive but have never had a sting reaction, this means you are sensitized but not necessarily clinically allergic. In this situation, a positive test on its own does not warrant immunotherapy. The decision rests on your clinical history.